Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mda2-targeted manganese g8 dendrimers
- Development stage
- Preclinical
- Lead developer
- Icahn School of Medicine
- Modality
- Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
MDA2-targeted manganese G8 dendrimers are a diagnostic agent designed for in vivo magnetic resonance (MR) imaging of atherosclerotic lesions. This construct utilizes G8 dendrimers, a type of nanoparticle, conjugated with manganese (via MnDTPA) to serve as an MR contrast agent. The specificity of the agent is achieved through the covalent attachment of the MDA2 antibody, a murine IgG monoclonal antibody, which targets malondialdehyde (MDA)-lysine epitopes. These oxidation-specific epitopes (OSE) are key factors in atherosclerotic plaque progression and destabilization. The drug aims to deliver a high payload of manganese to macrophage-rich plaques, enabling enhanced detection and imaging of these lesions, offering a potentially clinically translatable alternative to gadolinium-based agents.
- Other names
- manganese G8 dendrimers targeted to oxidation-specific epitopestargeted dendrimersmanganese-labeled dendrimers
02
Targets
MDA-Lys OSE (Malondialdehyde-lysine oxidation-specific epitope)
Beyond the preview
Go deeper on mda2-targeted manganese g8 dendrimers.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mda2-targeted manganese g8 dendrimers.